Allgenesis Biotherapeutics has unveiled encouraging data from its Phase Ib clinical trial of AG-80308 aqueous solution eye drop to treat dry eye disease (DED).
The double-masked, multi-centre study has assessed the tolerability, safety, and dose response of two formulations of AG-80308 in 84 patients with DED.
Formulation A including 0.001%, 0.03%, or 0.1% and formulation B with 0.03% were given two times a day for three months.
AG-80308, a formyl peptide receptor (FPR) agonist, showed improvements in tear production, conjunctival staining, and corneal staining responders.
Symptomatic improvements were also observed in the seven-item visual analogue scale, including photophobia, foreign body sensation, pain, itching, eye dryness, burning/stinging, and dry eye discomfort.
Among all the formulations, 0.001% of formulation A and 0.03% of formulation B provided the best efficacy profile, tolerability, and overall safety.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Allgenesis Biotherapeutics CEO Dr Madhu Cherukury said: “We are very encouraged with our data showing that patients are seeing improvements in multiple signs and symptoms from the Phase Ib trial as early as two weeks.
“AG-80308 can offer dry eye patients an effective treatment that can be used long-term without the AEs associated with other therapies.”
The company is planning to commence a Phase II trial of AG-80308 in the first quarter of next year.
Allgenesis Biotherapeutics chief medical officer Dr Sunil Patel said: “With the positive results from the Phase Ib trial, we are looking forward to moving this programme into Phase II, where we will evaluate two doses of AG-80308 in formulation B against the vehicle.
“This will be an ideal drug for treating chronic dry eye patients due to its unique MOA and excellent potency.”